SOURCE Faruqi & Faruqi, LLP
This patient-monitoring device-maker has plenty of room for growth.
Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate
Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.
Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.